Developments increasing our understanding of chronic urticaria have resulted in the simplification and improvement of available treatments.
Chronic urticaria (CU) is characterized by the recurrence of itchy hives and/or angioedema for more than 6 weeks.
Background: Data on the prevalence and disease management of chronic urticaria (CU) and chronic spontaneous urticaria (CSU) in the pediatric population are scarce. This study assessed the prevalence of CU and CSU, and disease management among pediatric patients (0-17 years).
Novartis announced new baseline results from a real world study of 3,733 chronic urticaria (CU) patients showing many are not...
Areas covered: The authors review crisaborole in the management of AD based on Phase II, Phase III, and post-marketing studies. Pharmacologic properties such as chemistry, pharmacokinetics, pharmacodynamics and metabolism are discussed.
A new global guideline on chronic urticaria (CU) recommends Xolair (omalizumab), indicated as add-on therapy for the treatment of chronic...
Areas covered: This review examines the current literature in respect to several different monoclonal antibodies that are being studied toward a personalized approach in the treatment of AD.
The effectiveness of corticosteroids in antihistamine-resistant chronic urticaria (CU) is widely accepted although large studies on their use in this disease are lacking.
Objective: To describe disease burden, quality of life (QoL), and treatment patterns of patients with H1 antihistamine refractory CSU in Germany.
Chronic spontaneous urticaria, formerly also known as chronic idiopathic urticaria and chronic urticaria (CU), is more common than previously thought.